Rabeprazole Sodium

Rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 signaling pathway. Rabeprazole inhibits the viability of gastric cancer cells in vitro and may serve as a novel antineoplastic agent. The pharmacokinetics of rabeprazole were described with good precision following administration of rabeprazole across a range of doses and in a range of formulations. Rabeprazole and esomeprazole were similarly effective when administered after a meal. Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy.